Written by Angela Kelly

Da Volterra Announces Results from Clinical Trial DAV132

Da Volterra, a French biopharmaceutical company, has announced the stunning results from the clinical study of DAV132. DAV132 was shown in a study of 44 healthy volunteers to protect the native gut flora, while taken in conjunction with an antibiotic. DAV132 did not compromise the effectiveness of the antibiotic and reduced exposure of the intestinal microbiota to moxifloxacin by 99%. With DAV132, the microbiome stayed almost entirely undisturbed.

https://www.businesswire.com/news/home/20180116005398/en/Da-Volterra-Announces-Publication-Full-Results-Clinical

SHEA Updates Contact Precautions Recommendations

The Society for Healthcare Epidemiology of America (SHEA) updated guidelines for how long hospitals should maintain contact precautions for antibiotic-resistant infections and C. diff infections. New guidelines suggest that for C. diff infections, precautions should be extended for at least 48 hours after resolution of diarrhea.

https://www.medscape.com/viewarticle/891242

Factors that Drive C. diff Recurrence

Contagion Live Peer-Panel discusses factors that lead to recurrence: over-treatment, dormant spores, and intestinal microbiome abnormality.

http://www.contagionlive.com/peer-exchange/managing-clostridium-difficile-infections/factors-that-impact-c-difficile-infection-recurrence

Read more from Angela at http://www.gutsymother.com/.